• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home Uncategorized

[Physician Comment] BRCA test results predict utilization of bilateral risk-reducing salpingo-oophorectomy

bys25qthea
February 3, 2013
in Uncategorized
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

Feb 3rd – JAMA – In spite of limited evidence for their use in this population, a substantial portion of women with uninformative BRCA test results chose to undergo RRSO and ovarian cancer screenings.

[tabs tab1=”2MM Rundown” tab2= “2MM Full Report”]

[tab]

Image: PD

1. In spite of limited evidence for their use in this population, a substantial portion of women with uninformative BRCA test results chose to undergo RRSO and ovarian cancer screenings.

2. Positive BRCA 1 or 2 status was a strong predictor for undergoing subsequent ovarian cancer screenings and bilateral, risk-reducing salpingo-oophorectomy (RRSO).

The results of this study show that BRCA test result (positive, negative or uninformative) is predictive of patient utilization of ovarian cancer screenings (CA-125, TVUS) and risk-reducing procedures (RRSO). In this study, women with a positive BRCA test result were much more likely to undergo screenings and salpingo-oophorectomies, while women with negative BRCA results were unlikely to do so. Despite limited evidence that screenings and RRSO’s lower morbidity in this population, more than a third of women with uninformative BRCA results chose to undergo ovarian cancer screenings and over 12% underwent RRSO.

RELATED REPORTS

Maintenance olaparib, compared with placebo, reduces the risk of disease progression in patients with advanced BRCA mutation ovarian cancer

#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018

#VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

This study has a number of limitations. Because women with a greater interest in ovarian cancer are more likely to complete this survey, the results of this study may be subject to selection bias. While the study population was diverse, the generalizability of this study’s results may be limited due to variations in patient and physician attitudes toward screening and risk management, which may have changed since the study period ended 5 years ago. Further exploration of what drives patient decisions to elect for screenings and RRSO, including pairing family history with BRCA results, would provide useful insight into how to revise guidelines and improve patient education and expectation management.

Click to read the study in the current issue of JAMA

Click to read an accompanying editorial in JAMA

[/tab]

[tab]

Image: PD

1. In spite of limited evidence for their use in this population, a substantial portion of women with uninformative BRCA test results chose to undergo RRSO and ovarian cancer screenings.

2. Positive BRCA 1 or 2 status was a strong predictor for undergoing subsequent ovarian cancer screenings and bilateral, risk-reducing salpingo-oophorectomy (RRSO).

Study author Gabriel N. Mannis, M.D. talks to to 2 Minute Medicine: Clinical Fellow in Hematology/Oncology at UCSF

jkkl“The key finding of this study is that the vast majority of women referred for testing–over 70%–receive uninformative results, and that despite a lack of guidelines for these women, a substantial percentage of them went on to have screening tests or prophylactic surgeries. These findings highlight the need for further cancer-risk stratification in a significantly understudied population whose cancer risk is likely quite heterogeneous. On a broader level, these findings highlight that with any cancer screening program, a negative test does not always allay patient fears and physicians must play a key role in discussing the potential risks and benefits of any screening test with their patients.”

 

 

This [retrospective cohort] study compared rates of ovarian cancer screening and risk-reduction procedures post-BRCA testing at two hospital sites. Authors surveyed 1077 women who were BRCA tested from 1996-2008, divided them into groups by test result (positive, negative or uninformative) and assessed utilization of ovarian cancer screenings (serum cancer antigen 125 (CA-125) and transvaginal ultrasonography, TVUS) and RRSO.

Women who tested positive for BRCA mutations (1 or 2) were more likely to undergo ovarian cancer screenings via serum CA-125 (OR 13.0; CI 5.5-29.0) and TVUS (OR 9.5, CI 4.3-21.0) and much more likely to elect for a risk-reducing bilateral salpingo-oophorectomy (RRSO) (OR 28.1; CI 16.2-48.6). Women with a negative BRCA result were unlikely to undergo these procedures. Despite receiving an uninformative BRCA test results, 12.3% of women reported undergoing RRSO. Additionally over a third of women with uninformative test results reported undergoing screenings via serum CA-125 and TVUS (33.8% and 37.3%, respectively).

In sum: The results of this study show that BRCA test result (positive, negative or uninformative) is predictive of patient utilization of ovarian cancer screenings (CA-125, TVUS) and risk-reducing procedures (RRSO). In this study, women with a positive BRCA test result were much more likely to undergo screenings and salpingo-oophorectomies, while women with negative BRCA results were unlikely to do so. Despite limited evidence that screenings and RRSO’s lower morbidity in this population, more than a third of women with uninformative BRCA results chose to undergo ovarian cancer screenings and over 12% underwent RRSO.

This study has a number of limitations. Because women with a greater interest in ovarian cancer are more likely to complete this survey, the results of this study may be subject to selection bias. While the study population was diverse, the generalizability of this study’s results may be limited due to variations in patient and physician attitudes toward screening and risk management, which may have changed since the study period ended 5 years ago. Further exploration of what drives patient decisions to elect for screenings and RRSO, including pairing family history with BRCA results, would provide useful insight into how to revise guidelines and improve patient education and expectation management.

Click to read the study in the current issue of JAMA

Click to read an accompanying editorial in JAMA

By Denise Pong and Leah Hawkins

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

[/tab]

[/tabs]

Tags: brca
Previous Post

Active-Duty U.S. servicewomen have higher rates of unintended pregnancy

Next Post

Early initiation of antiretroviral therapy significantly improves HIV survival [Classics Series]

RelatedReports

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Genetics

Maintenance olaparib, compared with placebo, reduces the risk of disease progression in patients with advanced BRCA mutation ovarian cancer

November 2, 2021
#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018
StudyGraphics

#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018

December 16, 2020
#VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
StudyGraphics

#VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

January 29, 2020
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Obstetrics

Olaparib plus bevacizumab for ovarian cancer maintenance therapy

January 7, 2020
Next Post

Early initiation of antiretroviral therapy significantly improves HIV survival [Classics Series]

Health information technology improves obesity treatment access and screening, but not patient outcomes

[Researcher Comment] Corticosteroid injections for tennis elbow associated with poorer recovery versus placebo

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.